Evidence map›Paper›PMID 24830314›Full record

ArticlePloS one2014

Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Amal Arachiche, María de la Fuente, Marvin T Nieman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Humanized murine models of platelet function.Current opinion in hematology · 2025
    Review
  5. Article
  6. Species Differences in Platelet Protease-Activated Receptors.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Targeting PAR1: Now What?Trends in pharmacological sciences · 2017
    Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amal ArachicheDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States of America.
María de la FuenteDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States of America.
Marvin T NiemanDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States of America.
Case Western Reserve University · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
The role of protease activated receptors on platelets.R01HL098217 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI NIEMAN, MARVIN THOMAS · 2010 to 2024
$4.6M
NCI NIH HHS P30 CA043703NCI NIH HHS P30 CA43703NHLBI NIH HHS HL098217NHLBI NIH HHS R01 HL098217
6 · The paper itself

Abstract

The in vivo study of protease activated receptors (PARs) in platelets is complicated due to species specific expression profiles. Human platelets express PAR1 and PAR4 whereas mouse platelets express PAR3 and PAR4. Further, PAR subtypes interact with one another to influence activation and signaling. The goal of the current study was to generate mice expressing PAR1 on their platelets using transgenic approaches to mimic PAR expression found in human platelets. This system would allow us to examine specific signaling from PAR1 and the PAR1-PAR4 heterodimer in vivo. Our first approach used the mouse GPIbα promoter to drive expression of mouse PAR1 in platelets (GPIbα-Tg-mPAR1). We obtained the expected frequency of founders carrying the transgene and had the expected Mendelian distribution of the transgene in multiple founders. However, we did not observe expression or a functional response of PAR1. As a second approach, we targeted human PAR1 with the same promoter (GPIbα-Tg-hPAR1). Once again we observed the expected frequency and distributing of the transgene. Human PAR1 expression was detected in platelets from the GPIbα-Tg-hPAR1 mice by flow cytometry, however, at a lower level than for human platelets. Despite a low level of PAR1 expression, platelets from the GPIbα-Tg-hPAR1 mice did not respond to the PAR1 agonist peptide (SFLLRN). In addition, they did not respond to thrombin when crossed to the PAR4-/- mice. Finally, we used an alternative platelet specific promoter, human αIIb, to express human PAR1 (αIIb-Tg-hPAR1). Similar to our previous attempts, we obtained the expected number of founders but did not detect PAR1 expression or response in platelets from αIIb-Tg-hPAR1 mice. Although unsuccessful, the experiments described in this report provide a resource for future efforts in generating mice expressing PAR1 on their platelets. We provide an experimental framework and offer considerations that will save time and research funds.

Indexed as

Promoter Regions, GeneticAnimalsBlood PlateletsGene ExpressionHumansMice, Inbred C57BLMice, KnockoutOrgan SpecificityPlatelet Glycoprotein GPIb-IX ComplexReceptor, PAR-1Transcriptional ActivationTransgenesadhesion receptorPlatelet Glycoprotein GPIb-IX ComplexReceptor, PAR-1

Identifiers

PMID24830314
PMCPMC4022678
OpenAlexW2160880203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.